Bioventus Inc. (BVS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Bioventus Inc. (BVS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.86

-0.30 (-3.28%)

At close: Jan 14, 2025, 3:59 PM

8.28

-6.57%

After-hours Jan 14, 2025, 05:32 PM EST

undefined% (undefined)

Bid	8.01
Market Cap	579.16M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.6
PE Ratio (ttm)	-14.77
Forward PE	n/a
Analyst	Strong Buy

Ask	9.7
Volume	244,242
Avg. Volume (20D)	377,475
Open	9.18
Previous Close	9.16
Day's Range	8.84 - 9.31
52-Week Range	3.90 - 14.38
Beta	undefined

About BVS

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones,...

[Show more]

Industry Medical - Devices

Sector Healthcare

IPO Date Feb 11, 2021

Employees 1,030

Stock Exchange NASDAQ

Ticker Symbol BVS

Website https://www.bioventus.com

Analyst Forecast

According to 3 analyst ratings, the average rating for BVS stock is "Strong Buy." The 12-month stock price forecast is $15, which is an increase of 69.30% from the latest price.

Buy 66.67%

Hold 33.33%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Bioventus Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of $144.83M, reflecting a 6.95% YoY growth and earnings per share of 0.08, making a 14.29% increase YoY.

Why Price Moved

2 months ago · Source

-16.27%

Bioventus shares are trading lower. The company re... Unlock content with Pro Subscription

3 months ago · Source

+5.34%

Bioventus shares are trading higher after Craig-Hallum maintained a Buy rating on the stock and raised its price target from $12 to $17.

News

1 week ago · zacks.com

BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.

3 weeks ago · zacks.com

Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Here is how Bioventus (BVS) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

1 month ago · zacks.com

Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Bioventus (BVS). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago · seekingalpha.com

Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS ) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President and CEO Mark Singleton - Sen...

2 months ago · zacks.com

Bioventus (BVS) Matches Q3 Earnings Estimates

Bioventus (BVS) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.05 per share a year ago.

2 months ago · zacks.com

Are Medical Stocks Lagging Bioventus (BVS) This Year?

Here is how Bioventus (BVS) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

2 months ago · zacks.com

Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings?

Investors will likely focus on the sales performance of BVS across the Pain Treatments and Surgical Solutions franchises when it reports third-quarter results.

2 months ago · zacks.com

Bioventus Surges 73% in Three Months: Time to Buy the Stock?

BVS generates encouraging returns, driven by rapid sales growth across the Pain Treatments and Surgical Solutions franchises.